NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01718379,Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality.,https://clinicaltrials.gov/study/NCT01718379,,COMPLETED,"The goal of the present study is to assess, through a randomized phase II trial, the efficacy and safety of Lenalidomide with or without Epoetin beta in transfusion-dependent, ESA-resistant, IPSS low and intermediate-1 risk MDS patients without chromosome 5 abnormality.

Patients will receive either Lenalidomide alone or Lenalidomide and Epoetin beta for 4 months. Responders will be eligible for maintenance treatment with cycles identical to the first cycles, until relapse occurs or until unacceptable toxicity.",NO,Myelodysplastic Syndromes,DRUG: Lenalidomide|DRUG: Epoetin beta,"Comparing the efficacy of Lenalidomide alone to Lenalidomide with Epoetin beta in transfusion-dependent ESA-resistant, Primary outcome is a complete or partial response defined by the IWG 2006 criteria observed after 4 months of treatment. Comparison in the rate of response between the two groups will be performed with Chi-square test or if necessary Fisher exact test.

Same analyzes will be performed with the IWG 2000 response definition ., After 4 months of treatment","will be to assess the safety of Lenalidomide and of its combination with Epoetin beta, * Safety of Lenalidomide and of its combination with Epoetin beta: adverse events (type, frequency, severity) and relationship of adverse events to study drug
* % of major HI-E and minor HI-E after 4 courses according to IWG 2000 criteria
* Erythroid response duration
* Time to response
* Time to progression according to IPSS
* RBC transfusion independence
* Prognostic factors of response
* Survival
* Quality of life, After 2 months of treatment",,Groupe Francophone des Myelodysplasies,Celgene|Roche Pharma AG,ALL,"ADULT, OLDER_ADULT",PHASE2,132,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,GFM-Len-Epo-08,2010-07,2012-11,2016-06,2012-10-31,,2016-11-08,"Hematology Dpt, Service d'Hématologie Clinique, CHU Albert Michallon, Grenoble, 38043, France|Hematology Dpt, CHU de Bicêtre, Le Kremlin-Bicêtre, Ile de France, 94275, France|Hematology Dpt, CHU Cochin, Paris, Ile de France, 75679, France|Chu Amiens, Amiens, 80054, France|CHU Angers, Angers, 43033, France|Hematology Dpt, CH d'Avignon-305 rue Follereau-, Avignon, 84000, France|CH de la Cote Basque, Bayonne, 64 100, France|centre de Blois, Blois, 41016, France|Hopital Avicenne, Bobigny, 93009, France|Hematology Dpt, CHU Haut-Lévèque, Bordeaux, 33604, France|Hôpital Boulogne Sur Mer, Boulogne Sur Mer, 62321, France|hôpital Morvan, Brest, 29609, France|CHU Clémenceau, Caen, 14033, France|CH de Carcassonne, Carcassonne, 11890, France|Hematology Dpt, CH René Dubos, Cergy-pontoise, 95303, France|CHU de Clermont-Ferrand, Clermont-Ferrand, 63058, France|CH de Compiègne, Compiègne, 60321, France|Hematology Dpt, Hôpital Sud Francilien, Corbeil-essonnes, 91100, France|hopital Henri Mondor, Créteil, 94010, France|CHU de Dijon, Dijon, 21034, France|Hematology Dpt, Hôpital Versailles, Le Chesnay, 78157, France|Hematology Dpt,CH Le mans, Le mans, 72037, France|CHRU Huriez, Lille, 59037, France|Hopital Saint-Vincent de Paul, Lille, 59160, France|CHRU de Limoges, Limoges, 87046, France|Hematology Dpt, Centre Hospitalier Lyon Sud, Lyon, 69495, France|CH de Mantes-la-jolie, Mantes-la-jolie, 78201, France|Institut Paoli Calmettes, Marseille, 13009, France|Hematology Dpt, CHU Brabois, Nancy, 54511, France|Hematology Dpt, CHU de nantes, Nantes, 44093, France|Hematology Dpt, CHU Archet, Nice, 06202, France|Hematology Dpt, CHU Caremeau, Nimes, 30029, France|Hematology Dpt, CHR La Source orléans, Orléans, 45067, France|centre René Huguenin, Paris Saint Cloud, 92210, France|Hematology Dpt, Hôpital la pitié-Salpétrière, Paris, 75013, France|Hematology Dpt, Hopital Saint Louis, Paris, 75475, France|Hopital Saint Antoine, Paris, 75571, France|Hematology Dpt, Hôpital Maréchal Joffre, Perpignan, 66046, France|Hôpital Jean Bernard, Poitiers, 86021, France|Hematology Dpt, Centre Hospitalier de la région d'Annecy, Pringy cedex, 74374, France|CHRU de Reims, Reims, 51092, France|CHU Pontchaillou, Rennes, 35033, France|Centre Henri Becquerel, Rouen, 76038, France|CH de Saint Quentin, Sint Quentin, 02321, France|Chu Strasbourg, Strasbourg, 67098, France|Hematology Dpt, CHU PURPAN, Toulouse, 31059, France|Hematology Dpt, CH CHU Bretoneau, Tours, 37044, France|centre hopitalier princesse Grace, Monaco, 98012, Monaco",
